Kingchem (Liaoning) Life Science Co., Ltd.

SZSE:301509 Stock Report

Market Cap: CN¥3.3b

Kingchem (Liaoning) Life Science Past Earnings Performance

Past criteria checks 2/6

Kingchem (Liaoning) Life Science has been growing earnings at an average annual rate of 11.3%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 8.3% per year. Kingchem (Liaoning) Life Science's return on equity is 3.1%, and it has net margins of 11.7%.

Key information

11.3%

Earnings growth rate

4.8%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate8.3%
Return on equity3.1%
Net Margin11.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

A Look At The Fair Value Of Kingchem (Liaoning) Life Science Co., Ltd. (SZSE:301509)

Sep 29
A Look At The Fair Value Of Kingchem (Liaoning) Life Science Co., Ltd. (SZSE:301509)

We Think Kingchem (Liaoning) Life Science (SZSE:301509) Can Stay On Top Of Its Debt

Feb 27
We Think Kingchem (Liaoning) Life Science (SZSE:301509) Can Stay On Top Of Its Debt

Revenue & Expenses Breakdown

How Kingchem (Liaoning) Life Science makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:301509 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 245686711035
30 Jun 245979411733
31 Mar 2467715011729
31 Dec 2376717411830
30 Sep 2373615312629
30 Jun 2377417311528
31 Mar 2374315210628
01 Jan 2371716110526
30 Sep 2271417910723
30 Jun 2267014810425
31 Mar 226091169725
31 Dec 21549859025
31 Dec 20464597721
31 Dec 19415586917
31 Dec 18301275813

Quality Earnings: 301509 has high quality earnings.

Growing Profit Margin: 301509's current net profit margins (11.7%) are lower than last year (20.7%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 301509's earnings have grown by 11.3% per year over the past 5 years.

Accelerating Growth: 301509's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 301509 had negative earnings growth (-56.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).


Return on Equity

High ROE: 301509's Return on Equity (3.1%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 19:24
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kingchem (Liaoning) Life Science Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution